Paul-Ehrlich-Institut

Im­muno­log­i­cal Medicines for Rab­bits

Immunological veterinary medicinal products, including vaccines, are authorised for rabbits.

Name De­scrip­tion Mar­ket­ing Au­tho­ri­sa­tion Hold­er Li­cense Num­ber Li­cense Date An­i­mal Further Information

CU­NI­VAK COM­BO

Myx­o­matose, Rab­bit Haem­or­rhag­ic Dis­ease (RHD)

IDT Bi­ologi­ka GmbH

PEI.V.07962.01.1 05.08.2009 Kaninchen

CU­NI­VAK ENT

Epi­zoo­tis­che En­teropathie

IDT Bi­ologi­ka GmbH

PEI.V.11641.01.1 17.07.2013 Kaninchen

CU­NI­VAK JET

Myx­o­matose

IDT Bi­ologi­ka GmbH

43a/92 14.10.2003 Kaninchen

CU­NI­VAK MYXO

Myx­o­matose

IDT Bi­ologi­ka GmbH

42a/92 14.10.2003 Kaninchen

CU­NI­VAK PAST

Kan­inchen­schnupfen

IDT Bi­ologi­ka GmbH

4a/96 01.04.1997 Kaninchen

CU­NI­VAK RHD

Rab­bit Haem­or­rhag­ic Dis­ease (RHD)

IDT Bi­ologi­ka GmbH

206a/92 11.05.2004 Kaninchen

Er­avac

Rab­bit Haem­or­rhag­ic Dis­ease (RHD)

Lab­o­ra­to­rios Hipra S.A., Spanien

EU/2/16/199-/001-002 26.09.2016 Kaninchen

EPAR: Er­avac

Filavac VHD K C+V

Rab­bit Haem­or­rhag­ic Dis­ease (RHD)

FILAVIE, Rous­say, Frankre­ich

PEI.V.11900.01.1 13.03.2017 Kaninchen

No­bi­vac Myxo-RHD

Myx­o­matose, Rab­bit Haem­or­rhag­ic Dis­ease (RHD)

In­ter­vet In­ter­na­tion­al BV, Nieder­lande

EU/2/11/132/002-004 07.09.2011 Kaninchen

EPAR: No­bi­vac Myxo-RHD

No­bi­vac Myxo-RHD PLUS

Myx­o­matose, Rab­bit Haem­or­rhag­ic Dis­ease (RHD)

In­ter­vet In­ter­na­tion­al B.V., Nieder­lande

EU/2/19/244/001-003 19.11.2019 Kaninchen

EPAR: No­bi­vac Myxo-RHD Plus

RI­KA - VACC RHD

Rab­bit Haem­or­rhag­ic Dis­ease (RHD)

Ecuphar NV, Bel­gien

200a/91 04.09.2003 Kaninchen

RI­KA-VACC Duo

Myx­o­matose, Hä­m­or­rhagis­che Krankheit (RHD)

Ecuphar NV, Bel­gien

PEI.V.03071.01.1 12.06.2008 Kaninchen

RI­KA-VACC Myxo sc

Myx­o­matose

Ecuphar NV, Bel­gien

PEI.V.03157.01.1 12.06.2008 Kaninchen

Hints

Disclaimer

The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.

The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.

As of: PEI announcement No. 477 in BAnz AT 16.02.2021 B7.

Summary of Product Characteristics (SmPCs) and the Package Leaflet (PL)

Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.

If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.

Updated: 01.03.2021